Bayer to partner with Twist Bioscience to accelerate drug discovery
Twist Bioscience eligible to receive up to USD 188 million
06-Oct-2023 -
Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform.
The company’s “Library of Libraries”, a collection of synthetic antibody libraries that harness innovative ...
antibodies
drug discovery